TRI ACT 2

TRI ACT 2 contains Glimepiride 2 mg + Metformin 500 mg (SR) + Pioglitazone 15 mg, a triple-combination therapy designed for effective control of type 2 diabetes. Glimepiride stimulates insulin release, Metformin improves insulin sensitivity and reduces glucose production, while Pioglitazone enhances peripheral glucose utilization. Together, they help achieve better glycemic control, stabilize blood sugar levels, and support long-term diabetes management.